These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 27428425)

  • 21. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
    Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ
    Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H; Kong X; Ribas A; Lo RS
    Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
    Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
    Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
    Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
    Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
    Chhabra G; Ahmad N
    J Invest Dermatol; 2022 May; 142(5):1256-1259. PubMed ID: 34872726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
    Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
    Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
    Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
    Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
    PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
    Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
    J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y
    Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
    Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A
    Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
    Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
    Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.
    Rebecca VW; Wood E; Fedorenko IV; Paraiso KH; Haarberg HE; Chen Y; Xiang Y; Sarnaik A; Gibney GT; Sondak VK; Koomen JM; Smalley KS
    Mol Cell Proteomics; 2014 Jul; 13(7):1844-54. PubMed ID: 24760959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.
    Chien AJ; Haydu LE; Biechele TL; Kulikauskas RM; Rizos H; Kefford RF; Scolyer RA; Moon RT; Long GV
    PLoS One; 2014; 9(4):e94748. PubMed ID: 24733413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.